FIELD: medicine.
SUBSTANCE: invention relates to medicine and is intended for the treatment of hepatic steatosis induced by a high fat diet (HFD). Calebin-A is orally administered in effective concentration.
EFFECT: method makes it possible to weaken the accumulation of triglycerides, hepatocellular balloon dystrophy and inflammatory infiltration and improve the efficiency of treatment.
1 cl, 11 tbl, 4 ex, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CALEBIN-A POTENTIAL AS ANTI-OBESITY AGENT | 2012 |
|
RU2543334C1 |
| COMPOSITION CONTAINING SCIRPUSIN A AND SCIRPUSIN B, AND ITS POTENTIAL AS ANTIOBESITY AGENT | 2015 |
|
RU2691404C2 |
| KALEBIN A FOR TREATMENT OF OSTEOPOROSIS | 2016 |
|
RU2653103C2 |
| METHOD OF INHIBITING SUCTION AND/OR INCREASING LIPID RELEASE WITH USING D-PSICOSE | 2016 |
|
RU2725145C2 |
| ANTICANCER ACTIVITY OF (E)-1-(3',4'-DIMETHOXYPHENYL)BUTADIENE | 2016 |
|
RU2694053C1 |
| SYNERGISTIC SELENOPEPTIDE PREPARATIONS FOR PROTECTION OF DERMAL PAPILLARY CELL | 2012 |
|
RU2606752C2 |
| HEPATOPROTECTIVE ACTION OF GARCINOL | 2011 |
|
RU2585245C2 |
| METHOD OF PREPARATION OF EXTRACELLULAR METABOLITES OF BACILLUS COAGULANS AND ITS BIOLOGICAL APPLICATIONS | 2014 |
|
RU2617965C2 |
| METHOD FOR LEAN MUSCLE MASS GAIN AND FATTY TISSUE REDUCTION | 2007 |
|
RU2456985C2 |
| USE OF COMPOSITIONS CONTAINING BIFIDOBACTERIUM ANIMALIS SSP. LACTIS LMG P-28149 | 2015 |
|
RU2673341C2 |
